Moving from Mounjaro 2.5mg to 5mg: what actually changes

Why does treatment start at 2.5mg rather than going straight to 5mg?

Many people are surprised to find that their first Mounjaro pen contains only 2.5mg of tirzepatide when the licensed range runs all the way to 15mg. The reason is straightforward: tirzepatide works by activating both GIP and GLP-1 receptors involved in appetite and blood-sugar regulation, and doing that from a standing start can provoke quite significant nausea in some patients. The starter dose exists to settle your digestive system before any meaningful dose escalation begins.

This matters for expectations. At 2.5mg you are unlikely to notice dramatic changes in appetite or weight, and that is by design. The NHS patient information for tirzepatide describes 2.5mg explicitly as a starting dose for tolerability, not the intended therapeutic level. If you are wondering how the starter dose compares in detail to the next step, the guide to moving from Mounjaro 2.5mg to 5mg covers the clinical differences side by side.

The practical upshot: do not judge the treatment by what the first pen does. Think of those four weeks as a calibration period rather than the main event.

When should the increase from 2.5mg to 5mg happen?

The licensed schedule sets a minimum of four weeks at each dose before moving up, and the step from 2.5mg to 5mg follows that same principle. In practice, your prescriber reviews how you tolerated the starting pen before confirming the increase is appropriate. If side effects were significant at 2.5mg, staying there a little longer is a legitimate clinical decision — there is no benefit in rushing.

At nume, every repeat order is reviewed by a prescriber before it is dispensed, which means the move to 5mg is assessed individually rather than being automatic. Evidence of how you tolerated the starter dose forms part of that review. For context on what the 5mg pen itself involves once you are there, the 5mg Mounjaro page goes into more detail on that dose specifically.

A practical note on timing: if you order by noon on a working day and your prescription is approved, your next pen is dispatched the same day and arrives via tracked DPD delivery the following working day, so there is no reason to leave it to the last minute and risk a gap between pens.

What changes in how you feel when you move from 2.5mg to 5mg?

For most people, the 5mg pen brings a noticeably stronger reduction in appetite. The medication's effect on gastric emptying (how quickly food leaves your stomach) becomes more pronounced, which is both the mechanism of weight loss and the reason nausea, if you experienced any at 2.5mg, can briefly return or increase around the transition.

The most commonly reported side effects across both doses are gastrointestinal: nausea, loose stools, constipation, reflux, burping and, less often, vomiting. These tend to be most prominent in the first few days after a dose change and generally ease as your body adapts. The NHS tirzepatide guidance lists these alongside the rarer but more serious signs, severe persistent stomach pain that radiates to the back warrants urgent medical attention, as this can indicate pancreatitis. If you are ready to move beyond 5mg and want to understand what that next step involves, the guide to moving from 5mg to 7.5mg Mounjaro covers the transition in detail. If you want a fuller picture of side effects at all doses, the broader Mounjaro treatment overview covers this in context.

Injection-site reactions are also possible; rotating between the abdomen, thigh and upper arm helps. Storage requirements stay the same: refrigerated at 2–8°C, with a limited window at room temperature, your pen's Patient Information Leaflet gives the exact figures, and it is worth checking that before your first injection at the new dose.

Is there anything specific to manage around the contraceptive pill or other medicines at this point?

This is a question our prescribers hear regularly, and it is worth addressing clearly. Because tirzepatide slows gastric emptying, it can affect how quickly oral medicines (including the combined contraceptive pill) are absorbed. UK guidance is specific: women taking an oral contraceptive should use an additional non-oral method, such as condoms, for the first four weeks of starting Mounjaro and for four weeks after every dose increase. That includes the step from 2.5mg to 5mg, and if you are just beginning the programme our Mounjaro 2.5mg page explains what to expect from that first pen in more detail.

The same principle applies to HRT: NHS England advises discussing transdermal options (patches or gels) with your doctor while on tirzepatide, for the same absorption reason. These interactions are flagged during your consultation and repeat review at nume, but they are worth keeping in mind independently.

For a broader look at how tirzepatide fits into the cost of private weight-loss treatment, including information on the tirzepatide 60 mg supply option, the treatment and pricing overview lays out what is included with a full course. If you are weighing up the wider context of the programme, our about page explains how the service is structured.